Thirty Years of Pneumococcal Conjugate Vaccines in Children: Achievements, Challenges and Lessons From a Moving Target.

Abstract

To review the long-term epidemiological and immunological impact of pneumococcal conjugate vaccines (PCVs) in the context of serotype replacement and the development of higher-valency formulations. Brief literature overview of current evidence on pneumococcal biology, natural and vaccine-induced immunity, population-level effects of PCVs and the epidemiological dynamics of serotype distribution. PCVs have profoundly reshaped the landscape of paediatric infectious diseases, leading to a dramatic decline in Streptococcus pneumoniae infections in children and, through herd protection, in adults. The decline in vaccine-type infections has been partially offset by the gradual emergence of non-vaccine serotypes. However, despite this serotype replacement, PCVs remain among the most powerful paediatric vaccines ever developed. The diversity of pneumococcal biology, the interplay between natural and vaccine-induced immunity and the dynamic process of serotype replacement create a constantly moving target. The introduction of higher-valency vaccines, now including up to 15 or 20 serotypes, seeks to address this adaptation but faces intrinsic immunological limits. Three decades after the first clinical trials, our understanding of their long-term epidemiological and immunological impact is still evolving. Future vaccine strategies must optimize the balance between expanded serotype coverage and durable immune protection at both the individual and population levels.